Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

This was the stock's third consecutive day of losses.

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in ...

Revenue at North Chicago-based AbbVie dove by nearly 10% during the first few months of this year — a drop that comes as its bestselling drug Humira faces competition for the first time in the U ...

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

Lawmakers in Congress busily marking up bills on pharmacy middlemen this week might want to pay heed to AbbVie’sABBV-0.77%decrease; red down pointing triangle latest earnings results. Investors ...

AbbVie expects Botox to maintain market share as competition heats up. By Pratik Jain and Leroy Leo. January 10, 2024 6:29 PM UTC Updated January 10, 2024 ... Jan 10 (Reuters) - AbbVie ...